AH237 exhibits broad inhibitory activity against CARM1 and PRMT5, and although not yet evaluated in cancer models, its ability to reduce ADMA and SDMA levels suggests potential utility110, particularly in combination with agents such as GSK3368715 (PRMT1 inhibitor) and GSK3326595 (PRMT5 inhibitor), which show synergistic antitumor effects111. This evidence concerns the gene PRMT5 and cancer.